Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Aug 16, 2019

SELL
$7.67 - $10.63 $86,295 - $119,598
-11,251 Closed
0 $0
Q1 2019

May 13, 2019

BUY
$7.58 - $9.94 $3,327 - $4,363
439 Added 4.06%
11,251 $112,000
Q4 2018

Feb 13, 2019

BUY
$7.16 - $16.21 $77,413 - $175,262
10,812 New
10,812 $83,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.05B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track United Services Automobile Association Portfolio

Follow United Services Automobile Association and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of United Services Automobile Association, based on Form 13F filings with the SEC.

News

Stay updated on United Services Automobile Association with notifications on news.